Cidara Therapeutics options imply 20.0% move in share price post-earnings 15:11 CDTX Pre-earnings options… Story temporarily locked.
Oh shit Van is that the time release name? I told this kid from Korea to hold....
CDTX Cidara Therapeutics, Inc.
Stock Price & Overview
$1.670.12(+7.4%)<--------------
잘했어요
jalhaess-eoyo
Precigen options imply 35.3% move in share price post-earnings 15:04 PGEN Pre-earnings options… Story temporarily locked.
watch this one: Angry holders from a $1.75 secondary.
Precigen slumps ~15% on pricing $75M common stock offering
Precigen price target raised to $10 from $7 at Cantor Fitzgerald 01/30 PGEN Cantor Fitzgerald analyst Jennifer Kim raised the firm's price target on Precigen to $10 from $7 and keeps an Overweight rating on the shares following the company's showcase of complete clinical trial safety and efficacy data from the Phase 1 dose-escalation and expansion cohorts for PRGN-2012 for recurrent respiratory papillomatosis. PRGN-2012's data checked every box, and had the best efficacy and safety data the firm has seen for a therapeutic vaccine in RRP, which could support upwards of a greater than$1B market opportunity in the U.S., the analyst tells investors in a research note.